French independent pharma company Pierre Fabre has named Eric Ducournau as its new chief executive, taking over from Bertrand Parmentier who has announced his retirement. 7 May 2018
US pharma major Eli Lilly today announced that Leena Gandhi, a prestigious thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology on June 25, 2018 to lead immuno-oncology medical development. 2 May 2018
Grünenthal has announced that Philip Just Larsen is to join the company chief scientific officer (CSO) and member of the corporate executive board. 30 April 2018
A month after US healthcare giant Johnson & Johnson announced that its chief financial officer (CFO) Dominic Caruso was to retire after 12 years in the role and Takeda's finance boss left his job with the Japanese firm, France’s biggest pharma company has said that it is losing its long-standing CFO. 19 April 2018
Novartis’ Vas Narasimhan, who became chief executive of the company on February 1, has now found a replacement for his previous post as head of global drug development (GDD) and chief medical officer, naming John Tsai to the position. 19 April 2018
GlaxoSmithKline today revealed is has appointed Kevin Sin as senior vice president and head of worldwide business development for pharmaceuticals research and development. 18 April 2018
Menarini, one of Italy’s largest pharma companies and still headed by the founding Aleotti family, has decided to entrust the chairmanship of the company to an external manager coming from a large multinational, Dr Eric Cornut. 29 March 2018
After 19 years with the US healthcare giant Johnson & Johnson (NYSE: JNJ), Dominic Caruso, executive vice president, chief financial officer, has elected to retire in September 2018. 22 March 2018
Christine Roy-Duval has left her role as international clinical investigation director at French pharma major Sanofi’s diabetes unit to join metabolic diseases specialist Valbiotis. 21 March 2018
A year after relinquishing the leadership of the UK’s leading drugmaker, Sir Andrew Witty has been named chief executive of a fast-growing player in the pharmacy benefit manager (PBM) space. 14 March 2018
The departure of André Wyss, president of Novartis Operations, has prompted a series of structural and personnel changes at the top of the Swiss pharma major. 12 March 2018
Swiss pharma giant Roche today announced that Dr John Reed head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the USA effective April 2, 2018. 9 March 2018
James Kehoe, chief financial officer (CFO) of Takeda, is leaving his role with the Japanese pharma company to become global CFO of Walgreens Boots Alliance. 8 March 2018
The head of Japanese pharma major Astellas’ (TYO: 4503) US operations is moving to take up a top position at US CNS focussed drugmaker Alkermes (Nasdaq: ALKS). 1 March 2018
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024